high cholesterol and glp-1 Glucagon-like peptide 1 receptor agonists: cardiovascular benefits mechanisms of action glp 1 for high cholesterol

Ozempic has shown weight loss results in clinical trials, with participants achieving significant reductions in body weight and improvements in cardiometabolic risk factors

While the researchers did not find evidence that people who lost more body weight had a larger reduction in cardiovascular risk, they did find that larger decreases in waist circumference (a more sensitive marker of visceral fat) accounted for roughly a third of the reduction in cardiac risk in the semaglutide group, still leaving most of the benefit unexplained by changes in body composition

For best results, semaglutide GLP- 1 is not used as a stand-alone solution

In the case, the sisters modest weight improvement may benefit from female-specific hormonal environments (e.g., estrogen) that enhance GLP-1 receptor signaling, while the brothers limited response could be related to male-specific factors that blunt semaglutide-induced appetite suppression and energy expenditure regulation